| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1045117454 |
| P356 | DOI | 10.1038/NM0195-53 |
| P698 | PubMed publication ID | 7584953 |
| P50 | author | Andrew Baird | Q38601164 |
| P2093 | author name string | Gage FH | |
| Takayama H | |||
| Hogg J | |||
| Ray J | |||
| Fisher LJ | |||
| Raymon HK | |||
| P2860 | cites work | GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons | Q24336322 |
| Endothelial cell-derived basic fibroblast growth factor: synthesis and deposition into subendothelial extracellular matrix | Q34613112 | ||
| Complementary DNA cloning and sequencing of rat ovarian basic fibroblast growth factor and tissue distribution study of its mRNA. | Q36438419 | ||
| Prospects of transplantation in human neurodegenerative diseases | Q36705345 | ||
| Cerebral transplantation for Parkinson's disease: current progress and future prospects | Q40909193 | ||
| Cooperative regulation of nerve growth factor synthesis and secretion in fibroblasts and astrocytes by fibroblast growth factor and other cytokines | Q42048245 | ||
| Monitoring of cell viability in suspensions of embryonic CNS tissue and its use as a criterion for intracerebral graft survival | Q42435290 | ||
| Transplantation of fetal dopamine neurons in Parkinson's disease: one-year clinical and neurophysiological observations in two patients with putaminal implants | Q44132651 | ||
| Morphological and neurochemical features of cultured primary skin fibroblasts of Fischer 344 rats following striatal implantation | Q46012400 | ||
| Cytokine regulation of nerve growth factor-mediated cholinergic neurotrophic activity synthesized by astrocytes and fibroblasts | Q46094030 | ||
| Selective and nonselective stimulation of central cholinergic and dopaminergic development in vitro by nerve growth factor, basic fibroblast growth factor, epidermal growth factor, insulin and the insulin-like growth factors I and II. | Q46172163 | ||
| Expression of biologically active basic fibroblast growth factor by genetically modified rat primary skin fibroblasts. | Q46190343 | ||
| Fibroblast growth factors stimulate nerve growth factor synthesis and secretion by astrocytes | Q46440006 | ||
| Basic fibroblast growth factor promotes the survival of embryonic ventral mesencephalic dopaminergic neurons--I. Effects in vitro. | Q48229447 | ||
| Survival, growth and function of dopaminergic neurons grafted to the brain | Q48230575 | ||
| Basic fibroblast growth factor ameliorates rotational behavior of substantia nigral-transplanted rats with lesions of the dopaminergic nigrostriatal neurons | Q48462217 | ||
| The neurotrophic effects of fibroblast growth factors on dopaminergic neurons in vitro are mediated by mesencephalic glia | Q48641595 | ||
| Fetal neural graft survival | Q48879920 | ||
| Storage, metabolism, and processing of 125I-fibroblast growth factor-2 after intracerebral injection. | Q54771577 | ||
| Fibroblast growth factors are present in the extracellular matrix produced by endothelial cells invitro: Implications for a role of heparinase-like enzymes in the neovascular response | Q56428985 | ||
| Brain Grafts Reduce Motor Abnormalities Produced by Destruction of Nigrostriatal Dopamine System | Q64821160 | ||
| Reconstruction of the nigrostriatal dopamine pathway by intracerebral nigral transplants | Q67019545 | ||
| Basic fibroblast growth factor enhances survival and sprouting of fetal dopaminergic cells implanted in the denervated rat caudate-putamen: preliminary observations | Q68377938 | ||
| Nimodipine enhances growth and vascularization of neural grafts | Q69057170 | ||
| Role of extracellular matrix in the action of basic fibroblast growth factor: matrix as a source of growth factor for long-term stimulation of plasminogen activator production and DNA synthesis | Q69639706 | ||
| Basic fibroblast growth factor promotes the survival of embryonic ventral mesencephalic dopaminergic neurons--II. Effects on nigral transplants in vivo | Q72624582 | ||
| Estimation of nuclear population from microtome sections | Q82126847 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Parkinson's disease | Q11085 |
| dopamine | Q170304 | ||
| P304 | page(s) | 53-58 | |
| P577 | publication date | 1995-01-01 | |
| P1433 | published in | Nature medicine | Q1633234 |
| P1476 | title | Basic fibroblast growth factor increases dopaminergic graft survival and function in a rat model of Parkinson's disease. | |
| P478 | volume | 1 |
| Q48363689 | A novel strategy for intrastriatal dopaminergic cell transplantation: Sequential “nest” grafting influences survival and behavioral recovery in a rat model of Parkinson's disease |
| Q30612948 | Activated astrocytes enhance the dopaminergic differentiation of stem cells and promote brain repair through bFGF |
| Q48715555 | Addition of lateral ganglionic eminence to rat mesencephalic grafts affects fiber outgrowth but does not enhance function |
| Q52197420 | Adenoviral vector-mediated gene transfer and neurotransplantation: possibilities and limitations in grafting of the fetal rat suprachiasmatic nucleus |
| Q42525516 | Astrocytic basic fibroblast growth factor expression in dopaminergic regions after perinatal anoxia. |
| Q48218354 | Basic fibroblast growth factor prevents the memory impairment induced by gastrin-releasing peptide receptor antagonism in area CA1 of the rat hippocampus |
| Q83206154 | Basic fibroblast growth factor protects against rotenone-induced dopaminergic cell death through activation of extracellular signal-regulated kinases 1/2 and phosphatidylinositol-3 kinase pathways |
| Q64814787 | Bilateral intracaudate cografting of fetal ventral mesencephalon and striatum in advanced Parkinson's disease |
| Q28140390 | Building brains: neural chimeras in the study of nervous system development and repair |
| Q28206557 | Cellular replacement therapy for Parkinson's disease--where we are today? |
| Q48393387 | Co-grafted embryonic striatum increases the survival of grafted embryonic dopamine neurons |
| Q64787878 | Co-grafts of muscle cells and mesencephalic tissue into hemiparkinsonian rats: behavioral and histochemical effects |
| Q43873807 | Combined neurotrophic supplementation and caspase inhibition enhances survival of fetal hippocampal CA3 cell grafts in lesioned CA3 region of the aging hippocampus |
| Q33809293 | Development of fetal neural transplantation as a treatment for Parkinson's disease |
| Q48098723 | Differential effects of Bcl-2 overexpression on fibre outgrowth and survival of embryonic dopaminergic neurons in intracerebral transplants. |
| Q64381079 | Dopa-producing astrocytes generated by adenoviral transduction of human tyrosine hydroxylase gene: in vitro study and transplantation to hemiparkinsonian model rats |
| Q44760131 | Dopaminergic neurons associate with blood vessels in neural transplants |
| Q42164678 | Dynamic regulation of fibroblast growth factor 2 (FGF-2) gene expression in the rat brain following single and repeated cocaine administration. |
| Q48826799 | Early effects of basic fibroblast growth factor on foetal rat mesencephalic cell suspensions |
| Q40619846 | Effect of glial cell line-derived neurotrophic factor (GDNF) co-transplantation with fetal ventral mesencephalic cells (VMC) on functional restoration in 6-hydroxydopamine (6-OHDA) lesioned rat model of Parkinson's disease: neurobehavioral, neuroche |
| Q54967971 | Effects of Passage Number and Differentiation Protocol on the Generation of Dopaminergic Neurons from Rat Bone Marrow-Derived Mesenchymal Stem Cells. |
| Q44131050 | Enhanced viability and neuronal differentiation of neural progenitors by chromaffin cell co-culture |
| Q34470156 | Enhancement of graft survival and sensorimotor behavioral recovery in rats undergoing transplantation with dopaminergic cells exposed to glial cell line—derived neurotrophic factor |
| Q33806616 | Ethical issues in neurografting of human embryonic cells |
| Q55474080 | Extensive neuronal localization and neurotrophic function of fibroblast growth factor 8 in the nervous system. |
| Q48609008 | FGF-2 deficiency does not alter vulnerability of the dopaminergic nigrostriatal system towards MPTP intoxication in mice. |
| Q44551336 | Fetal hippocampal CA3 cell grafts enriched with fibroblast growth factor-2 exhibit enhanced neuronal integration into the lesioned aging rat hippocampus in a kainate model of temporal lobe epilepsy |
| Q34458450 | Fetal tissue transplantation for patients with Parkinson's disease: a database of published clinical results |
| Q28507347 | Fibroblast growth factor (FGF)-2 and FGF receptor 3 are required for the development of the substantia nigra, and FGF-2 plays a crucial role for the rescue of dopaminergic neurons after 6-hydroxydopamine lesion |
| Q64765292 | Fibroblast growth factor-2-producing fibroblasts protect the nigrostriatal dopaminergic system from 6-hydroxydopamine |
| Q63286769 | Fibroblast growth factors |
| Q40775287 | GDNF is a major component of trophic activity in DA-depleted striatum for survival and neurite extension of DAergic neurons |
| Q34534274 | Gene therapy for Parkinson's disease |
| Q34455675 | Glial cell line-derived neurotrophic factor improves intrastriatal graft survival of stored dopaminergic cells |
| Q43578216 | Growth and functional efficacy of intrastriatal nigral transplants depend on the extent of nigrostriatal degeneration. |
| Q38138431 | Growth factor signaling and memory formation: temporal and spatial integration of a molecular network |
| Q41033079 | Growth factors improve immediate survival of embryonic dopamine neurons after transplantation into rats |
| Q40983994 | Growth/differentiation factor 5 and glial cell line-derived neurotrophic factor enhance survival and function of dopaminergic grafts in a rat model of Parkinson's disease. |
| Q35918287 | Human neural stem cells genetically modified for brain repair in neurological disorders |
| Q47985730 | Immunohistochemical analyses of fibroblast growth factor receptor-1 in the human substantia nigra. Comparison between normal and Parkinson's disease cases |
| Q41067317 | Implants of Polymer-Encapsulated Genetically Modified Cells Releasing Glial Cell Line-Derived Neurotrophic Factor Improve Survival, Growth, and Function of Fetal Dopaminergic Grafts |
| Q34120728 | Improving the survival of grafted embryonic dopamine neurons in rodent models of Parkinson's disease |
| Q31873495 | Inhibitors of p38 MAP kinase increase the survival of transplanted dopamine neurons |
| Q48586493 | Intracerebral Transplantation of Testis-Derived Sertoli Cells Promotes Functional Recovery in Female Rats with 6-Hydroxydopamine-Induced Hemiparkinsonism |
| Q48702567 | Intrastriatal grafts of embryonic mesencephalic rat neurons genetically modified using an adenovirus encoding human Cu/Zn superoxide dismutase |
| Q48360064 | Long-Lasting Induction of Astrocytic Basic Fibroblast Growth Factor by Repeated Injections of Amphetamine: Blockade by Concurrent Treatment with a Glutamate Antagonist |
| Q41235622 | Neuronal progenitors as tools for cell replacement in the nervous system |
| Q40636683 | Neurospheres modified to produce glial cell line-derived neurotrophic factor increase the survival of transplanted dopamine neurons |
| Q35165435 | Neurotrophic factors for the investigation and treatment of movement disorders |
| Q37322226 | Neurotrophic factors in neurodegenerative disorders : potential for therapy |
| Q48491947 | Neurotrophic factors in neurodegenerative disorders: model of Parkinson's disease |
| Q41172471 | New directions in the drug treatment of Parkinson's disease |
| Q36225073 | New therapeutic approaches to Parkinson's disease including neural transplants. |
| Q41671598 | Novel therapeutic directions for Parkinson's disease |
| Q39446326 | Optimal Effectiveness of BDNF for Fetal Nigral Transplants Coincides with the Ontogenic Appearance of BDNF in the Striatum |
| Q40542389 | Overexpression of glial cell line-derived neurotrophic factor induces genes regulating migration and differentiation of neuronal progenitor cells. |
| Q44574700 | Pretreatment of donor cells with FGF-2 enhances survival of fetal hippocampal CA3 cell transplants in the chronically lesioned young adult hippocampus |
| Q34515354 | Prospects for the treatment of Parkinson's disease using neurotrophic factors |
| Q40429860 | Radical directions in Parkinson's disease |
| Q36364388 | Shedding light into the role of BDNF in the pharmacotherapy of Parkinson's disease. |
| Q34747162 | Somatic cell cloned transgenic bovine neurons for transplantation in parkinsonian rats |
| Q40799364 | Sonic hedgehog facilitates dopamine differentiation in the presence of a mesencephalic glial cell line. |
| Q41008595 | Strands of embryonic mesencephalic tissue show greater dopamine neuron survival and better behavioral improvement than cell suspensions after transplantation in parkinsonian rats |
| Q37822930 | Strategies for the development of cell lines for ex vivo gene therapy in the central nervous system |
| Q73455130 | Striatal trophic activity is reduced in the aged rat brain |
| Q48196755 | Temporo-spatial expression of bFGF and TGFbeta2 in embryonic dopaminergic grafts in a rat model of Parkinson's disease |
| Q39427473 | Testis-derived Sertoli cells have a trophic effect on dopamine neurons and alleviate hemiparkinsonism in rats |
| Q40911146 | The Use of Nonneuronal Cells for Gene Delivery |
| Q48891118 | The colayer method as an efficient way to genetically modify mesencephalic progenitor cells transplanted into 6-OHDA rat model of Parkinson's disease |
| Q44010211 | The controlled conversion of human neural progenitor cells derived from foetal ventral mesencephalon into dopaminergic neurons in vitro |
| Q47229270 | The high molecular weight fibroblast growth factor-2 isoforms (21,000 mol. wt and 23,000 mol. wt) mediate neurotrophic activity on rat embryonic mesencephalic dopaminergic neurons in vitro |
| Q48521197 | Transgene expression in rat fetal brain grafts is maintained for 7 months after ex vivo adenoviral vector-mediated gene transfer |
| Q48242730 | Transplantation of expanded mesencephalic precursors leads to recovery in parkinsonian rats |
| Q37762259 | Use of growth factors for the treatment of Parkinson's disease |
Search more.